New fears over the variants!
Oxford/AstraZeneca COVID-19 shot less effective against South African variant
British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.
The study from South Africa’s University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.
Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.
“In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant,” an AstraZeneca spokesman said in response to the FT report.
The newspaper said none of the more than 2,000 trial participants had been hospitalized or died.
Just days ago, it was reported that more than 4,000 variants are making their way around the planet ..
“Its very unlikley that the current vaccine won’t be effective on the variants whether in Kent or other variants especially when it comes to severe illness and hospitalization,” Vaccine Deployment Minister Nadhim Zahawi told Sky News in the UK..
“All manufacturers, Pfizer-Biontech, Moderna, Oxford-AstraZeneca and others are looking at how they can improve their vaccine to make sure that we are ready for any variant – there are about 4,000 variants around the world of COVID now.”